Astrazeneca (AZN) said Saturday the full results from the Phase III trial showed Tezspire or tezepelumab, an asthma treatment jointly developed with Amgen (AMGN), led to significant reductions in nasal polyp severity, surgery requirements, and systemic corticosteroid use for patients with chronic rhinosinusitis with nasal polyps, compared with placebo.

At week 52, Tezspire improved the co-primary endpoints, reducing Nasal Polyp Score by -2.065 and nasal congestion by -1.028 compared with placebo, with benefits observed as early as weeks four and two respectively.

These findings were published in the New England Journal of Medicine and presented at the American Academy of Allergy Asthma & Immunology and World Allergy Organization Joint Congress in San Diego, California on Saturday.